Merck & Co., Inc. (MRK) Shares Sold by Papp L Roy & Associates

Share on StockTwits

Papp L Roy & Associates lowered its stake in Merck & Co., Inc. (NYSE:MRK) by 3.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 12,613 shares of the company’s stock after selling 404 shares during the quarter. Papp L Roy & Associates’ holdings in Merck & Co., Inc. were worth $964,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Martingale Asset Management L P increased its stake in shares of Merck & Co., Inc. by 0.7% in the 3rd quarter. Martingale Asset Management L P now owns 694,680 shares of the company’s stock worth $49,281,000 after purchasing an additional 5,121 shares in the last quarter. Baker Avenue Asset Management LP increased its stake in shares of Merck & Co., Inc. by 2.5% in the 3rd quarter. Baker Avenue Asset Management LP now owns 32,890 shares of the company’s stock worth $2,333,000 after purchasing an additional 792 shares in the last quarter. Signaturefd LLC increased its stake in shares of Merck & Co., Inc. by 5.7% in the 3rd quarter. Signaturefd LLC now owns 21,620 shares of the company’s stock worth $1,534,000 after purchasing an additional 1,165 shares in the last quarter. Covington Capital Management increased its stake in shares of Merck & Co., Inc. by 2.9% in the 3rd quarter. Covington Capital Management now owns 204,640 shares of the company’s stock worth $14,517,000 after purchasing an additional 5,841 shares in the last quarter. Finally, EP Wealth Advisors LLC increased its stake in shares of Merck & Co., Inc. by 124.4% in the 3rd quarter. EP Wealth Advisors LLC now owns 12,649 shares of the company’s stock worth $897,000 after purchasing an additional 7,012 shares in the last quarter. 73.85% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have recently commented on the company. ValuEngine lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. Zacks Investment Research upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $93.00 price target for the company in a research note on Monday, April 1st. Atlantic Securities upgraded Merck & Co., Inc. from a “neutral” rating to an “overweight” rating in a research note on Monday, May 13th. They noted that the move was a valuation call. Cantor Fitzgerald reiterated a “buy” rating and issued a $95.00 price target on shares of Merck & Co., Inc. in a research note on Friday, March 29th. Finally, UBS Group increased their price target on Merck & Co., Inc. from $87.00 to $88.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $82.92.

Shares of MRK stock opened at $78.72 on Friday. Merck & Co., Inc. has a 52-week low of $57.49 and a 52-week high of $83.85. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $212.24 billion, a price-to-earnings ratio of 18.14, a price-to-earnings-growth ratio of 1.86 and a beta of 0.58.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.17. Merck & Co., Inc. had a return on equity of 39.85% and a net margin of 19.50%. The business had revenue of $10.82 billion during the quarter, compared to analyst estimates of $10.45 billion. During the same quarter in the prior year, the business posted $1.05 EPS. Merck & Co., Inc.’s revenue for the quarter was up 7.8% compared to the same quarter last year. Analysts expect that Merck & Co., Inc. will post 4.72 EPS for the current year.

In other news, EVP Frank Clyburn sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $77.73, for a total transaction of $1,943,250.00. Following the completion of the transaction, the executive vice president now owns 92,604 shares in the company, valued at $7,198,108.92. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Richard R. Deluca sold 35,000 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $80.00, for a total value of $2,800,000.00. Following the transaction, the executive vice president now owns 106,064 shares of the company’s stock, valued at approximately $8,485,120. The disclosure for this sale can be found here. Insiders sold a total of 673,712 shares of company stock valued at $54,776,448 in the last quarter. 0.27% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Merck & Co., Inc. (MRK) Shares Sold by Papp L Roy & Associates” was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://weekherald.com/2019/05/19/merck-co-inc-mrk-shares-sold-by-papp-l-roy-associates.html.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Story: Asset Allocation and Your Retirement

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.